BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-05-17 pm EDT | ||
| 12.1 EUR | -2.41% |
|
| Current month | +1.25% | ||
| 1 month | +7.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 12.04 | -2.93% |
| 24-05-16 | 12.4 | -0.51% |
| 24-05-15 | 12.47 | +0.75% |
| 24-05-14 | 12.38 | +1.43% |
| 24-05-13 | 12.2 | +3.54% |
Real-time Euronext Paris
Last update May 17, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| UD92S | |
| ISIN | DE000SV2PVQ8 |
| Date issued | 2023-03-27 |
| Strike | 455.3 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.49 € |
|---|---|
| Lowest since issue | 2.076 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- UD92S Certificat